HPK1-IN-2 (example A1; 75-150 mg/kg; oral gavage; daily; for 21 days) treatment shows a dose-dependently tumor growth inhibition, with 75 mg/kg and 150 mg/kg QD inhibiting tumour growth by 44% and 64%, respectively[1].
| Animal Model: | Female BALB/c mice (6-8week old) injected with CT26 cancer cells[1] |
| Dosage: | 75 mg/kg and 150 mg/kg |
| Administration: | Oral gavage; daily; for 21 days |
| Result: | Showed a dose-dependently tumor growth inhibition. |
